Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (DE:38I)
FRANKFURT:38I
Ntla-2002, Normal Saline Iv Administration
Hereditary Angioedema
Phase III
Active Not Recruiting
HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)
Oct 07, 2024
―
Biological Ntla-3001
Pulmonary Disease, Lung Disease, Alpha-1 Antitrypsin Deficiency, Aatd, Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Phase I/II
Withdrawn
NTLA-3001 in Adults with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease
Sep 30, 2024
―
Ntla-2001
Transthyretin-Related (Attr) Familial Amyloid Polyneuropathy, Transthyretin-Related (Attr) Familial Amyloid Cardiomyopathy, Wild-Type Transthyretin Cardiac Amyloidosis
Phase I
Active Not Recruiting
Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2001 in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and Patients With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)
Oct 19, 2020
―
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Intellia Therapeutics (38I) have in its pipeline
38I is currently developing the following drugs: Ntla-2002, Normal Saline Iv Administration, Biological Ntla-3001, Ntla-2001. These drug candidates are in various stages of clinical development as the company works toward FDA approval.